Intra-articular Mesenchymal Stem Cell Therapy for the Human Joint: A Systematic Review

McIntyre, James A.; Jones, Ian A.; Han, Bo; Vangsness, C. Thomas

doi:10.1177/0363546517735844

Cited by 125 publications

(98 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 56 Recent clinical trials showed a decrement of pain, an enhancement of joint performance, and a high quality of cartilage repair in knee OA, following MSC treatment. 57 Exosomes were also shown to be involved in the IBDs, which are a set of chronic disorders that occur when intestinal homeostasis is impaired. 12 One of the many mechanisms underlying these diseases is represented by the immune response modulated by macrophage activity.…”

Section: Exosomes In Different Chronic Pain Conditionsmentioning

confidence: 99%

Exosomes as a new pain biomarker opportunity

et al. 2020

View full text Add to dashboard Cite

Exosomes are extracellular microvesicles implicated in intercellular communication with ability to transfer cargo molecules, including protein, lipids, and nucleic acids, at both close and distant target sites. It has been shown that exosomes are implicated in physiological and pathological processes. In recent years, the interest on exosomes’ role in many pain states has increased. Their involvements in pain processes have been demonstrated by studies on different chronic pain diseases, both inflammatory and neuropathic, such as osteoarthritis, rheumatoid arthritis, inflammatory bowel diseases, neurodegenerative pathologies, complex regional pain syndrome, and peripheral nerve injury. Animal and clinical studies investigated exosomes-based treatments, showing their ability to improve painful symptoms with fewer side effects, with potential immunoprotective and anti-inflammatory effect. Specific molecular patterns characterize exosomes’ cargo according to the cellular origin, epigenetic modifications, environmental state, and stressor factors. Therefore, the identification of specific cargo’s profile associated to pain states may lead to recognize specific pathological states and to consider the use of exosomes as biomarkers of diseases. Furthermore, exosomes’ ability to transfer information and their presence in many accessible biological fluids suggest a potential use as novel non-invasive therapeutic tools in pain field.

show abstract

Section: Exosomes In Different Chronic Pain Conditionsmentioning

confidence: 99%

Exosomes as a new pain biomarker opportunity

et al. 2020

View full text Add to dashboard Cite

show abstract

“…When combined with the reality that existing treatment options are often suboptimal for many soft‐tissue injuries and that many patients seeking treatment are frequently relatively young and desirous of returning to an active lifestyle, an environment has been created in which patients are vulnerable and will seek such stem/progenitor cell treatments. However, although great potential exists for the use of cell‐based approaches to improve tissue healing and regeneration, the reality is that current data for the use of cell‐based therapies for augmentation of tissue healing is highly variable …”

Section: Key Question 5: What Are the Task Force Recommendations For mentioning

confidence: 99%

“…However, although great potential exists for the use of cell-based approaches to improve tissue healing and regeneration, the reality is that current data for the use of cell-based therapies for augmentation of tissue healing is highly variable. 111,112 Given this significant limitation, it is imperative that patients are informed that there exists little highlevel animal model or randomized clinical trial data to support the use of stem/progenitor cell-based approaches for tissue healing. It should also be communicated to patients that use of these treatment approaches are most often off-label, and that the treating facility often has a financial incentive to perform a stem/progenitor cell procedure which is unlikely to be covered by standard medical insurance.…”

Section: Cell-based Therapy In Humansmentioning

confidence: 99%

American Society for Bone and Mineral Research‐Orthopaedic Research Society Joint Task Force Report on Cell‐Based Therapies – Secondary Publication

O’Keefe

Tuan

Lane

et al. 2020

Journal Orthopaedic Research

View full text Add to dashboard Cite

Cell‐based therapies, defined here as the delivery of cells in vivo to treat disease, have recently gained increasing public attention as a potentially promising approach to restore structure and function to musculoskeletal tissues. Although cell‐based therapy has the potential to improve the treatment of disorders of the musculoskeletal system, there is also the possibility of misuse and misrepresentation of the efficacy of such treatments. The medical literature contains anecdotal reports and research studies, along with web‐based marketing and patient testimonials supporting cell‐based therapy. Both the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) are committed to ensuring that the potential of cell‐based therapies is realized through rigorous, reproducible, and clinically meaningful scientific discovery. The two organizations convened a multidisciplinary and international Task Force composed of physicians, surgeons, and scientists who are recognized experts in the development and use of cell‐based therapies. The Task Force was charged with defining the state‐of‐the art in cell‐based therapies and identifying the gaps in knowledge and methodologies that should guide the research agenda. The efforts of this Task Force are designed to provide researchers and clinicians with a better understanding of the current state of the science and research needed to advance the study and use of cell‐based therapies for skeletal tissues. The design and implementation of rigorous, thorough protocols will be critical to leveraging these innovative treatments and optimizing clinical and functional patient outcomes. In addition to providing specific recommendations and ethical considerations for preclinical and clinical investigations, this report concludes with an outline to address knowledge gaps in how to determine the cell autonomous and nonautonomous effects of a donor population used for bone regeneration. © 2020 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:485–502, 2020

show abstract

“…While developments in stem cell therapy display the potential to regrow cartilage, the current body of work is comprised of poorquality evidence with widespread heterogeneity, a lack of reproducibility, and gaps in translating in vitro and preclinical findings to patient care. 84,85 By far, the most widely studied growth factor related treatment is platelet-rich plasma (PRP). PRP is produced by high-speed centrifugation of blood that leads to a supernatant with a platelet concentration well above baseline.…”

Section: Regenerative Medicinementioning

confidence: 99%

Nonsurgical Management of Cartilage Defects of the Knee: Who, When, Why, and How?

2020

View full text Add to dashboard Cite

The nonoperative practitioner managing individuals with cartilage defects should use a patient-centered, multifaceted approach that aims to individualize treatment to provide optimal benefit. These include addressing modifiable risk factors for disease progression and instituting interventions such as weight loss, nutrition, physical activity, and potentially regenerative medicine strategies. This review will focus on these nonoperative treatment strategies with a focus on when treatments are necessary, who will benefit from these approaches, why they are specifically appropriate, and, finally, how these treatments directly modify the structure of a patient's cartilage and resulting symptoms.

show abstract

Intra-articular Mesenchymal Stem Cell Therapy for the Human Joint: A Systematic Review

Abstract: This review provides strong evidence that autologous intra-articular MSC therapy is safe, with generally positive clinical outcomes.

Cited by 125 publications

References 50 publications

Exosomes as a new pain biomarker opportunity

Exosomes as a new pain biomarker opportunity

American Society for Bone and Mineral Research‐Orthopaedic Research Society Joint Task Force Report on Cell‐Based Therapies – Secondary Publication

Nonsurgical Management of Cartilage Defects of the Knee: Who, When, Why, and How?

Contact Info

Product

Resources

About